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Background. Clinical and experimental observations sug-
gest that proteinuria is not merely a marker of chronic
nephropathies, but may also be involved in the progression to
end-stage renal failure. Filtered proteins are taken up by tubular
cells, and overwhelming this system may lead to tubular synthe-
sis of various proinflammatory and profibrogenic cytokines, in-
cluding transforming growth factor-beta (TGF-b). TGF-b acts
by first binding to specific receptors. We studied in an in vitro
system using a well-defined mouse proximal tubular cell line
(MCT cells) whether fatty acid-free bovine albumin modulates
expression of specific receptors for TGF-b .
Methods. MCT (and LLC-PK1) cells were challenged in
serum-free medium with different concentrations of albumin.
Activation of a local renin-angiotensin system was tested by
real-time polymerase chain reaction (PCR) for renin and an-
giotensinogen transcripts and determination of secreted an-
giotensin II (Ang II) by enzyme-linked immunosorbent assay
(ELISA). Some cells were also treated with the AT1 receptor
antagonist losartan. TGF-b receptor types I and II mRNA levels
were determined by Northern analysis whereas protein abun-
dance was measured by Western blots. To test for a functional
consequence of up-regulated TGF-b receptors, MCT cells were
preincubated with albumin and subsequently treated with low-
dose TGF-b that normally does not induce collagen type IV ex-
pression by itself. Downstream signaling events were detected
by Western blots for phosphorylated Smad2. Scatchard assays
with [125I]TGF-b1 were performed to estimate affinity and num-
ber of specific binding sites. Different length TGF-b type II
promoter constructs linked to CAT reporter were transiently
transected into MCT cells to determine transcriptional activity.
Results. Incubation of MCT cells with 0.5 to 10 mg/mL al-
bumin leads to an increase in type II TGF-b receptor mRNA
and protein expression without influencing type I receptors.
An increase in type II TGF-b receptor protein expression was
detected after 12 hours of albumin incubation and was still
detectable after 48 hours. The albumin-mediated increase in
1See Editorial by Imai, p. 2085.
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type II TGF-b receptor mRNA was attenuated in the pres-
ence of 1 lmol/L losartan, suggesting involvement of a local
renin-angiotensin system. MCT cells treated with albumin sig-
nificantly increased expression of angiotensinogen and renin
transcripts and also secreted more Ang II into the culture
supernatant. Analysis of transcriptional activity showed that
promoter segments containing activating protein (AP-1)-
binding sites are necessary for albumin-induced transcription
of the TGF-b type II receptor. Binding assays revealed that
albumin treatment significantly increased the overall binding
sites as well as the affinity for TGF-b . This effect had func-
tional consequences because MCT cells pretreated with albu-
min reacted with a stronger TGF-b–mediated phosphorylation
of down-stream Smad2 and also increased collagen IV expres-
sion compared with control cells.
Conclusion. Our findings indicate that albumin up-regulates
ligand-binding TGF-b receptors on cultured proximal tubular
cells. Albumin-induced activation of local Ang II production
appears to be responsible for this effect. This may amplify the
matrix-stimulatory actions of TGF-b on tubular cells and could
be a novel mechanism for how proteinuria exhibits pathophys-
iologic effects on tubular cells ultimately leading to tubuloint-
erstitial fibrosis.
Proteinuria is a common finding in many renal diseases.
Although traditionally considered to be a marker of re-
nal injury, there is increasing evidence that proteinuria
plays a key role in the tubulointerstitial changes that ul-
timately lead to renal insufficiency [1, 2]. There is a good
correlation between the severity of tubulointerstitial in-
jury and the amount of proteinuria [3]. Furthermore, clin-
ical as well as experimental data suggest that proteinuria
is closely involved in proinflammatory and profibrotic
changes of the tubulointerstitium [4, 5]. In vitro stud-
ies have demonstrated that albumin, one of the major
components found in proteinuria of glomerular origin,
induces proinflammatory, profibrotic, and vasoactive fac-
tors in cultured proximal tubular cells [6–9]. A key factor
leading to tubulointerstitial fibrosis and tubular atrophy
is transforming growth factor-beta (TGF-b). It has been
previously shown by in vitro and in vivo studies that al-
bumin activates the tubular synthesis of TGF-b . [6, 9,
10]. This profibrogenic cytokine could then locally stimu-
late collagen biosynthesis in tubular cells and interstitial
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fibroblasts and also increase proliferation of fibroblasts
[10]. Moreover, recent evidence suggests that TGF-b is
important for the transdifferentiation of tubular cells into
interstitial fibroblasts that may explain, at least to some
extent, the tubular atrophy in chronic nephropathies [11].
Since the actions of TGF-b , including the stimulation
of extracellular matrix (ECM) proteins, are mediated by
specific receptors for this cytokine [12], it is possible that
the overall profibrogenic activity of TGF-b is also in-
fluenced by the presence and surface density of specific
receptors.
The present study was undertaken to test the hypoth-
esis that albumin may modulate expression of TGF-b
receptors in cultured murine proximal tubular (MCT)
cells [13]. Our results suggest that albumin stimulates
TGF-b receptor type II transcription, synthesis, and sur-
face expression in cultured proximal tubular cells. This
mechanism may contribute to the profibrogenic effects
of TGF-b on proximal tubular cells under proteinuric
conditions.
METHODS
Cell culture
MCT cells are a proximal tubular cell line originally
isolated from adult SJL (H-2s) mice [13]. Although MCT
cells represent a permanent cell line, they do express
many features of proximal tubular cells and have been
used by many investigators as a model system to study the
function of proximal tubules in vitro [13–16]. For some
additional control experiments, LLC-PK1 cells, a porcine
cell line with some properties of proximal tubular cells,
were used [17]. Cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 450 mg/dL glucose,
100 U/mL penicillin, 100 lg/mL streptomycin, 2 mmol/L
supplemental glutamine, and 10% heat-inactivated fetal
calf serum (FCS) (Gibco-BRL, Eggenstein, Germany) at
37◦C in 5% CO2. Cells were passaged every 96 hours by
light trypsination.
Angiotensin II (Ang II) secretion
To determine whether albumin may influence Ang II
production and secretion, MCT cells were incubated for
24 hours with 0.5 to 10 mg/mL bovine serum albumin
(BSA) (>97% albumin, essentially fatty acid-free from
Sigma, Deisenhofen, Germany). This albumin was endo-
toxin free (<0.5 ng/mL) as determined with the endotoxin
kit from Sigma. Ang II released into the supernatant was
directly measured by a specific solid-phase immobilized
epitope immunoassay [18] (IBL, Hamburg, Germany).
The limit of detection for this assay is 0.5 pg/mL. A stan-
dard curve was constructed with cell culture medium.
Cells were lysed and the protein content was determined
by with the Lowry method. Ang II concentrations are
expressed as pg/mg cellular protein. The experiment was
independently repeated four to five times for each albu-
min concentration.
Receptor binding studies
For receptor binding studies, 104 cells were plated per
well of a 24-well plate (Nunc Inc., Naperville, IL, USA),
and were rested for 24 hours in serum-free DMEM.
Cells were then treated for another 24 hours with 10
mg/mL albumin in DMEM or were kept in serum-
free DMEM. Binding studies were done in assay buffer
[serum-free DMEM with 5 mmol/L MgCl2, 10 mmol/L ε-
aminocaproic acid, 1 mmol/L phenylmethylsulfonyl fluo-
ride (PMSF), and 0.5% aprotinin] on a shaking platform
at 4◦C for 1 hour [19]. We have previously demonstrated
that saturation of TGF-b binding sites occurred after
40 minutes under these conditions [19]. For saturation
binding assays increasing amounts (0.5 to 100 pmol/L)
of human recombinant [125I]TGF-b1 (specific activity
2101 Ci/mmol) (Amersham, Braunschweig, Germany)
were added [19]. Nonspecific binding was determined in
the presence of 1 lmol/L human recombinant TGF-b1
(Sigma). After 1 hour, cells were gently washed three
times with ice-cold phosphate-buffered saline (PBS), and
proteins were precipitated with 10% trichloroacetic acid.
Finally, cells were lysed in 500 lL 0.5 mol/L NaOH with
0.5% Triton X-100, and the amount of radioactivity was
counted in a gamma scintillation counter. Control wells
without radioactivity were also lysed and protein content
was measured with the Lowry method. Nonspecific biding
was subtracted and data were analyzed with the computer
program Enzfitter (Elsevier-Biosoft, Cambridge, United
Kingdom). Results are presented as Scatchard plots of
saturation binding data and every point represents the
mean of four determinations [19].
Western blots
A total of 106 quiescent cells were treated for 12 to
48 hours in serum-free DMEM with 1 to 10 mg/mL
BSA. At the end of the stimulation period, cells were
washed twice in PBS, and cell monolayers were directly
lysed on ice in 150 lL of a buffer containing 2% sodium
dodecyl sulfate (SDS) and 60 mmol/L Tris-HCl (pH
6.8) supplemented with a cocktail of protease inhibitors
(CompleteTM) (Boehringer Mannheim, Germany) con-
taining antipain-HCl, chymostatin, leupeptin, bestatin,
pepstatin, phosphoramidon, aprotinin, and ethylenedi-
aminetetraacetic acid (EDTA). The protein content was
measured by a modification of the Lowry method. Pro-
tein concentrations were adjusted to 60 lg/sample, and
5% glycerol/0.03% bromophenol blue/10 mmol/L dithio-
threitol (DTT) were added, then samples were boiled
for 5 minutes. After centrifugation, supernatants were
loaded onto a denaturing 7.5% SDS-polyacrylamide
gel. High-molecular-weight markers (Rainbow markers)
(Amersham), which comprise 45,000 to 200,000 D, served
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as the molecular weight standards. After completion of
electrophoresis, proteins were electroblotted onto a ni-
trocellulose membrane (High-bond-N) (Amersham) in
transfer buffer (50 mmol/L Tris-HCl, pH 7.0, 380 mmol/L
glycine, 0.1% SDS, and 20% methanol). Filters were
stained with Ponceau S to control for equal load-
ing and transfer. The blots were blocked in 5%
nonfat dry milk in PBS with 0.1% Tween 20 for
1 hour at 22◦C. For the detection of TGF-b re-
ceptors, a 1:1000 dilution of rabbit polyclonal anti-
bodies generated against the mouse TGF-b receptors
types I and II (both from Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used. Washes, incubations
with horseradish peroxidase-conjugated antirabbit sec-
ondary antibodies, and detection using the enhanced
chemiluminescence (ECL) reagent (Amersham) were
performed according to the manufacturer’s recommen-
dations. For selected blots, membranes were washed for
30 minutes in PBS with 0.1% Tween-20 and were reincu-
bated with a mouse monoclonal antibody against b-actin
(1:2000 dilution) (Sigma) to control for small variations
in protein loading and transfer. Western blots were inde-
pendently repeated three times with qualitatively similar
results. Exposed films were scanned with Fluor-STM
multi-imager (Bio-Rad Laboratories, Hercules, CA,
USA), and data were analyzed with the computer pro-
gram Multi-AnalystTM (Bio-Rad). The intensity of the
bands from control cells (no albumin) was assigned an
arbitrary value of 1.0. If Western blots were reincubated
with an antibody against b-actin, the signal intensities
were normalized to b-actin.
To investigate whether albumin-treatment of MCT
cells may influence TGF-b–induced Smad signaling, cells
were incubated for 24 hours in either serum-free DMEM
or DMEM supplemented with 10 mg/mL albumin. Cells
were then treated with 0.5 ng/mL recombinant TGF-b1
(Sigma) for 30 minutes. Western blots were performed
with a rabbit antibody generated against phosphorylated
Smad2 using a 1:500 dilution (Cell Signaling, Beverly,
MA, USA). Membranes were reincubated with a mon-
oclonal antibody against total Smad2 (Cell Signaling)
(1:1000 dilution). Western blots for Smad2 were repeated
twice with qualitatively similar changes.
Northern blots
Quiescent MCT cells or LLC-PK1 cells were stim-
ulated for 24 hours with 1 to 10 mg/mL BSA. Some
cells also received 1 lmol/L of losartan, an AT1 receptor
antagonist (gift of Merck, Sharp & Dohme, Munich,
Germany). To test for a functional influence of up-
regulated TGF-b receptors, MCT cells were incubated
for 24 hours with 1 mg/mL albumin. After wash-
ing of cells with serum-free medium, 0.5 to 2 ng/mL
recombinant TGF-b1 (Sigma) were added for an-
other 12 hours. After washing in RNAse-free PBS,
cells were directly lysed with acid guanidinium thio-
cyanate, and total RNA was isolated. Equal amounts
of total RNA (15 lg per lane) were denatured in
formamide-formaldehyde at 65◦C and electrophoresed
through a 1.2% agarose gel containing 2.2 mol/
L formaldehyde. Blotting, hybridization, and washing
conditions were exactly as previously described [19].
cDNA probes for the mouse TGF-b receptors types I and
II were constructed by reverse transcription-polymerase
chain reaction (RT-PCR) based on the published se-
quences and were cloned into the TA vector (Invitro-
gen, Leek, The Netherlands). The probes used were a
306 bp EcoRI fragment encoding the mouse TGF-b re-
ceptor type I, and a 353 bp EcoRI fragment from the
mouse TGF-b receptor type II. These cDNA probes have
been previously used [19, 20]. For collagen type IV levels,
a 1300 bp mouse a1(IV) PstI cDNA fragment was used
[21]. For control hybridizations, a 2.0 kb cDNA insert
of the plasmid pMCI encoding the murine ribosomal 18S
band was used. Exposed films were scanned and analyzed
as described for Western blots. A ratio between the inten-
sities of the hybridization signals for TGF-b receptors or
collagen type IV versus 18S was calculated. Signals from
cells incubated in serum-free medium without albumin
were considered a relative value of 1.0. Northern blots
were repeated three times for TGF-b receptor expres-
sion and twice for collagen type IV hybridizations with
qualitatively similar results.
Real-time PCR
To assess potential changes in angiotensinogen and
renin mRNAs expression in MCT cells induced by al-
bumin, real-time PCR was performed. After isolation
of total RNA using the acid guanidinium thiocyanate
method, possible remaining DNA was digested with
RNAse-free DNAse I (Ambion, Austin, TX, USA).
After addition of DNAse inactivator reagent (Am-
bion) and centrifugation, 1 lg total RNA from each
sample was used for reverse transcription using the
SYBRTM Green RP-PCR kit from Applied Biosystems
(Foster City, CA, USA) with oligod(T)16 primers and
1.25 U MultiScribeTM reverse transcriptase. Amplifi-
cations for angiotensinogen/renin and glyceraldehyde-
3-phosphatase (GAPDH) were performed for each
cDNA sample with SYBRTM Green PCR Master mix
(Applied Biosystems) using the hot start technique
with AmpliTaqGoldTM DNA polymerase. The following
primer were used: mouse angiotensinogen (5′-CCTACT
TTTCAACACCTACGTTCACT-3′, 5′-GCTGTTGTCC
ACCCAGAATTC-3′) [22], mouse renin (Ren-1d) (5′-
CTCAGCCAGGACTCGGTGAC-3′, 5′-CCAGCATG
AAAGGGATCAGG-3′) [23], GAPDH (5′-ACCACA
GTCCATGCCATCAC-3′, 5-′TCCACCACCCTGTTG
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CTGTA-3′). The Abi PrismTM 7000 sequence detection
system (Applied Biosystems) was used. After an initial
hold of 2 minutes at 50◦C and 10 minutes at 95◦C, 40 cy-
cles were performed at 95◦C for 15 seconds, 58◦C (an-
giotensinogen) or 59◦C (renin, GAPDH) for 60 seconds,
and 65◦C for 60 seconds. After 40 cycles, the tempera-
ture was increased from 60 to 95◦C to construct a melting
curve. A control without cDNA was run in parallel with
each assay. The cDNA content of each specimen was de-
termined using comparative CT method with 2−CT. The
results are given as relative expression of angiotensino-
gen or renin normalized to the GAPDH housekeeping
gene. Signals from cells incubated without albumin were
considered a relative value of 1.0. Real-time RT-PCR ex-
periments were independently (stimulation of cells, RNA
isolation, reverse transcription, and PCR) performed six
times. In pilot experiments, PCR products run on agarose
gels revealed a single band.
Transient transfections and reporter gene assays
To test for potential Ang II–mediated transcriptional
activity of the TGF-b receptor type II, transient transfec-
tion of MCT cells were performed using LipofectinTM
(Gibco-BRL) according to the manufacturer’s recom-
mendations. Quiescent MCT cells (final density 105 cells)
were cotransfected with 10 lg of plasmids containing dif-
ferent regions of the human TGF-b receptor type II con-
nected to the CAT genes [24] (generous gift from Dr.
Seong-Jin Kim, National Cancer Institute, Bethesda, MD,
USA) and the same amount of the plasmid pSV-b galac-
tosidase in which the b-galactosidase gene is under con-
trol of SV40 promoter and enhancer. After 12 hours, the
serum-free medium was renewed and cells were incu-
bated for another 24 hours with serum-free medium con-
taining 0 to 10 mg/mL albumin. For selected experiments,
MCT cells were transfected with the 1240 construct/
pSV-b galactosidase and stimulated with 10 mg/mL albu-
min in the presence of 1 lmol/L losartan. Some cells were
also treated with 50 ng/mL of a pan-specific neutraliz-
ing anti-TGF-b1-3 antibody (R&D Systems, Minneapo-
lis, MN, USA). At the end of the experiments, cells were
washed three times in PBS, cell layers were lysed, and pro-
tein concentrations of supernatants were adjusted. CAT
and b-galactosidase protein concentrations were mea-
sured with specific enzyme-linked immunosorbent assay
(ELISAs) (Boehringer Mannheim, Mannheim, Ger-
many). A ratio between CAT and b-galactosidase con-
centrations was calculated, and data from unstimulated
control cells were considered as 1.0. Transient transfec-
tions and reporter gene assays were independently per-
formed four times for each construct.
Statistical analysis
All data are presented as the means ± SEM. Statisti-
cal significance between different groups was first tested
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Fig. 1. Scatchard transformation of binding data. [125I] transforming
growth factor-b1 (TGF-b1) saturation binding was performed with
MCT monolayers as described in the Methods section. Nonspecific bid-
ing was determined in the presence of 1 lmol/L TGF-b1 and was sub-
tracted from all data points. Preincubation of cells for 24 hours with 1
mg/dL albumin increased the number of specific TGF-b surface binding
sites (controls 320 fmol/mg protein, 1 mg/mL albumin for 24 hours: 400
fmol/mg protein) and the affinity of the binding site (Kd of controls 2.00
pmol/L, Kd of cells treated with albumin for 24 hours 1.6 pmol/L). Ev-
ery data point represents the mean of four independent determinations
() control medium, () albumin for 24 hours.
with the nonparametric Kruskal-Wallis test. Individual
groups were subsequently tested using the Wilcoxon-
Mann-Whitney test. A P value of <0.05 was considered
significant.
RESULTS
Receptor binding studies
We initially performed saturation binding studies to in-
vestigate whether albumin stimulation may influence ex-
pression of TGF-b receptors on MCT cells. As shown by
Scatchard analysis of binding data (Fig. 1), MCT cells ex-
pressed a single class of high affinity receptors for TGF-b
with characteristics similar to previous observations [19].
Preincubation of cells for 24 hours with 1 mg/mg albumin
enhanced the affinity of specific receptors for TGF-b (Kd
of controls 2.00 pmol/L, Kd of cells treated with albumin
for 24 hours 1.6 pmol/L). In addition, growing MCT cells
in the presence of albumin for 24 hours also increased
the overall number of specific binding sites for TGF-b
(controls 320 fmol/mg protein, 1 mg/mL albumin for 24
hours 400 fmol/mg protein). Since total binding sites were
calculated per mg protein, this increase reflects a true
upregulation of TGF-b receptors and not only an effect
mediated by albumin-induced cell growth.
TGF-b receptor protein expression
Western blots from whole cell lysates were per-
formed to evaluate TGF-b receptor protein expression.
Figure 2A demonstrates that the polyclonal rabbit anti-
TGF-b receptor type I detected one single band of
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Fig. 2. Western blots for transforming
growth factor-b (TGF-b) receptor type I
(A) and II (B) protein expression. (A) A
single band is shown of approximately 55
kD identical to the size of the type I TGF-b
receptor as previously described in MCT cells
as well as in other cell types. This blot was
reincubated with an antibody against b-actin
to control for small variations in loading and
protein transfer. Albumin (0.5 to 10 mg/mL)
for 24 hours failed to significantly increase
protein expression of the TGF-b receptor
type I in MCT cells. (B) In contrast, albumin
strongly stimulates protein expression of
the 70 kD TGF-b receptor type II in MCT
cells. Blots are representative for three
independent experiments.
approximately 55 kD, identical to the size previously
described in MCT cells as well as in other cell types [19,
25]. This blot was reincubated with an antibody against
b-actin to control for small variations in loading and pro-
tein transfer. However, albumin (0.5 to 10 mg/mL) for
24 hours failed to increase protein expression of the TGF-
b receptor type I in MCT cells (Fig. 2A) (0 mg/mL 1.0, 0.5
mg/mL 0.99 ± 0.03, 1 mg/mL 1.10 ± 0.04, and 10 mg/mL
1.12 ± 0.05 relative changes in TGF-b receptor type I
expression normalized to b-actin expression, not signifi-
cant) (N = 3). In contrast, albumin stimulates protein ex-
pression of the 70 kD TGF-b receptor type II in MCT cells
(Fig. 2B) (0 mg/mL 1.00, 0.5 mg/mL 4.52 ± 0.13∗, 1 mg/
mL 4.80 ± 0.22∗, and 10 mg/mL 5.12 ± 0.29∗ relative
changes in TGF-b receptor type II expression normal-
ized to b-actin expression) (∗P < 0.05 versus controls)
(N = 3). An increase of TGF-b receptor type II protein
expression was already detectable after 12 hours incuba-
tion with 10 mg/mL albumin and was still found after 48
hours (Fig. 3).
Activation of a local renin-angiotensin system
Since it has been previously shown that proteinuria
stimulates a local renin-angiotensin system in tubular
cells [26], we first studied whether similar mechanisms
are operative in our cell culture system. As shown in
Table 1, incubation of MCT cells for 24 hours with al-
bumin significantly increases angiotensinogen and renin
transcripts and also stimulated the secretion of Ang II
into the culture supernatant. We and others have also
previously shown that Ang II up-regulates TGF-b recep-
tor expression [19, 25]. Consequently, we next tested a
potential role of albumin-induced Ang II production in
mediating TGF-b receptor expression. Figure 4 demon-
strates that treatment with 1 lmol/L of the AT1-receptor
blocker losartan almost completely abolished albumin-
induced expression of TGF-b receptor type II protein
expression without influencing the type I receptor.
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Fig. 3. Time course for transforming growth factor-b (TGF-b) receptor
type II protein expression in MCT cells. Incubation with 10 mg/mL
albumin up-regulated TGF-b receptor type II after 12 to 48 hours. This
blot is representative for two independent experiments.
Table 1. Effect of albumin on tubular renin-angiotensin system
activation
Angiotensinogen Renin Angiotensin II
mRNA mRNA secretion
(relative increase) (relative increase) (pg/mg protein)
Controls 1.00 ± 0.00 1.00 ± 0.00 1.26 ± 0.10
0.5 mg/dL 1.26 ± 0.08a 1.32 ± 0.05a 1.69 ± 0.17
1 mg/dL 2.28 ± 0.99a 2.59 ± 1.25b 1.77 ± 0.13b
10 mg/dL 9.73 ± 6.32b 8.40 ± 3.99b 2.01 ± 0.12a
aP < 0.01 versus controls without albumin (N = 4 to 5); bP < 0.05 versus
controls without albumin.
mRNA expression
Northern blots were performed to investigate whether
albumin may also increase mRNA expression of TGF-b
receptors in MCT cells. Albumin (0.5, 1, and 10 mg/mL)
for 24 hours failed to change the amount of TGF-b recep-
tor type I transcripts in MCT cells (Fig. 5) (0 mg/mL 1.00,
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Fig. 4. Western blots for transforming
growth factor-b (TGF-b) receptor types I
and II. Treatment with 1 lmol/L losartan
(Los) has no influence on TGF-b receptor
type I expression (left panel). However, the
AT1-receptor antagonist almost completely
attenuated the albumin-induction of TGF-b
receptor type II protein expression (right
panel). Blots are representative for two
independent experiments.
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Fig. 5. Northern blots for transforming growth factor-b (TGF-b) re-
ceptor type I and II mRNAs prepared from MCT cells. Treatment with
albumin for 24 hours failed to change the amount of TGF-b receptor
type I transcripts (left panel). However, albumin clearly up-regulates
TGF-b receptor type II mRNA expression in MCT cells. These blots
are representative of three independent experiments with qualitatively
similar changes.
0.5 mg/mL 1.36 ± 0.12, 1.0 mg/mL 1.16 ± 0.61, and 10 mg/
mL 1.40 ± 0.51) (relative changes in mRNA expression,
not significant) (N = 3). In contrast, albumin clearly up-
regulates TGF-b receptor type II mRNA expression in
MCT cells with maximal effect at 1 to 10 mg/mL albumin
(Fig. 5) (0 mg/mL 1.00, 0.5 mg/mL 1.60 ± 0.10∗, 1.0 mg/
mL 1.71 ± 0.36∗, and 10 mg/mL 1.72 ± 0.17∗) (rela-
tive changes in mRNA expression) (∗P < 0.05) (N = 3).
Albumin-induced expression of TGF-b receptor type II
transcripts was not restricted to mouse MCT cells, but
was also found in LLC-PK1 cells, a porcine tubular cell
line (Fig. 6). In these cells, 0.5 mg/mL albumin induced a
strong upregulation of TGF-b receptor type II mRNA ex-
pression (0 mg/mL 1.00, 0.5 mg/mL 2.43 ± 0.50∗, 1.0 mg/
mL 1.52 ± 0.10∗, and 10 mg/mL 1.44 ± 0.21∗) (relative
changes in mRNA expression) (∗P < 0.05) (N = 3). As
shown in Figure 7, losartan treatment also completely
attenuated albumin-mediated expression of TGF-b re-
ceptor type II mRNA.
To further investigate whether the increase in TGF-b
receptor type II transcript expression after challenge with
albumin was due to a stimulated gene transcription vari-
ous lengths of 5′-specific promoter/enhancer elements of
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Fig. 6. Northern blot for transforming growth factor-b (TGF-b) recep-
tor type II. Treatment with albumin also increased TGF-b receptor type
II mRNA expression in LLC-PK1 cells, a porcine cell line with some
properties of proximal tubules. This blot is representative for three in-
dependent experiments with qualitatively similar changes.
the human TGF-b receptor type II gene linked to CAT
were transiently transfected into MCT cells. These con-
structs have been previously described [19, 24]. Construct
504 contains one activating protein-1 (AP-1)–binding
site whereas the full-length construct 1240 exhibits two
AP-1–binding sites. Cells were subsequently treated for
24 hours with 0.5 to 10 mg/mL albumin. Although higher
concentrations of albumin (1 mg/mL and 10 mg/mL)
numerically reduced transcription of the shortest con-
struct 47, these changes were not significant (Fig. 8A).
Transfection with the intermediate constructs 274 and 504
revealed no significant transcriptional activity after stim-
ulation with 0.5–10 mg/mL albumin (Fig. 8A). How-
ever, MCT cells transfected with the longest construct
1240, containing two putative AP-1 sites, showed a strong
significant stimulation of the reporter gene CAT after
stimulation with various albumin concentrations (Fig.
8A). Treatment of MCT cells with 1 lmol/L losartan
totally attenuated albumin-induced transcription of the
longest construct 1240 (Fig. 8B). However, coincubation
with a neutralizing pan anti-TGFb1-3 antibody did not
Wolf et al: Albumin and TGF-b receptor 1855
Co
ntr
ol
1 m
g/m
L a
lbu
mi
n
Co
ntr
ol +
 
Lo
s
1 m
g/m
L a
lbu
mi
n +
 
Lo
s
TGF-β RII
18 S
Fig. 7. Influence of losartan on albumin-mediated transforming
growth factor-b (TGF-b) receptor type II mRNA expression in MCT
cells by Northern blot. Treatment with 1 lmol/L losartan (Los) almost
completely attenuated the albumin-induced increase in TGF-b recep-
tor type II mRNA. This experiment was independently performed twice
with qualitatively similar results.
change albumin-induced activation of the 1240 constructs
suggesting that transcription is independent of TGF-b
(Fig. 8B).
Functional relevance
On TGF-b binding to TGF-b receptor type II, the type
I receptor is recruited into the complex and activated
[27, 28]. Activated TGF-b receptor type I then signals to
downstream intracellular substrates called Smads [29]. In
order to test a functional relevance of up-regulated TGF-
b receptors, we studied the phosphorylation of Smad2.
Figure 9 shows that a relatively low concentration of ex-
ogenous TGF-b1 (0.5 ng/mL) induced a much stronger
phosphorylation of Smad2 in MCT cells incubated for
24 hours in 10 mg/dL albumin compared to cells grown in
control medium without albumin. The protein expression
of total Smad2 was not different.
In addition, MCT cells were stimulated with exoge-
nous TGF-b and mRNA expression for a1(IV) collagen,
a typical TGF-b−induced ECM protein, was measured
to investigate whether up-regulation of TGF-b receptors
and the associated increase in Smad2 phosphorylation
translates into increased target gene activation. As shown
in Figure 10, TGF-b–induced a1(IV) collagen expres-
sion was enhanced in MCT cells previously incubated for
24 hours in 1 mg/mL albumin compared to controls. Un-
der this condition even a relatively low TGF-b concentra-
tion strongly induced a1(IV) collagen mRNA expression
(Fig. 10) (controls 1.00, 0.5 ng/mL TGF-b1 1.12 ± 0.34,
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Fig. 8. Results of reporter gene studies. (A) Different length constructs
encoding the transforming growth factor-b (TGF-b) receptor type II
promoter were transiently cotransfected with SV40-b-galactosidase in
MCT. Treatment with albumin (0.5 to 10 mg/mL) for 24 hours did not
influence transcription of constructs 47, 274, and 504 compared with un-
stimulated controls. However, MCT cells transfected with the longest
construct 1240 that contains two activating protein-1 (AP-1) binding
sites showed a strong significant stimulation of the reporter gene CAT
after albumin treatment. (B) Regulation of the longest construct 1240
was further investigated in detail. Administration of lmol/L losartan
completely abolished the albumin-induced activation. In contrast, a
neutralizing pan-anti-TGF-b antibody (50 ng/mL) had no effect. Mean
values of three to five independent transfections, stimulations, and re-
porter gene assays.
2 ng/m TGF-b1 1.14 ± 0.41, controls + albumin 1.20 ±
0.73, 0.5 ng/mL TGF-b1 + albumin 3.80 ± 0.2∗, 2 ng/mL
TGF-b1 + albumin 5.21 ± 0.85∗) (relative changes in
mRNA expression) (∗P < 0.05 versus corresponding
groups without albumin) (N = 2).
DISCUSSION
The present study tested whether albumin in a con-
centration found in proteinuria may influence expression
of TGF-b surface receptors on cultured proximal tubu-
lar cells. We found that albumin leads to transcriptional
up-regulation of the TGF-b receptor type II. This stimu-
lated gene transcription was reflected in increased TGF-b
receptor type II protein expression and was also demon-
strated by increased binding of TGF-b to cell surfaces
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Fig. 9. Western blot for Smad2. MCT cells were either grown in 10
mg/dL albumin for 24 hours or in Dulbecco’s modified Eagle’s medium
(DMEM) without albumin. Cells were then challenged with 0.5 ng/mL
exogenous transforming growth factor-b (TGF-b1) for 30 minutes.
MCT cells preincubated in albumin revealed a stronger phosphory-
lation of Smad2 after TGF-b1 treatment than those cells incubated in
albumin-free medium. Expression of total Smad2 did not change. This
blot is representative for two independent experiments with qualita-
tively similar results.
with a slightly increased affinity. Finally, preincubation
of MCT cells with albumin leads to a subsequent acceler-
ated TGF-b–mediated signal transduction pathways such
as Smad2 and also resulted in induction of a1(IV) colla-
gen mRNA suggesting a functional effect of this receptor
up-regulation. Since TGF-b receptor type II is primarily
engaged in the initial binding of TGF-b , an increased re-
ceptor expression may result in amplification of the TGF-
b effects on tubular cells.
TGF-b signaling involves two distantly related trans-
membrane serine/threonine kinases named receptors I
and II [27, 28]. The cytokine binds first to the type II re-
ceptor which is constitutively expressed in an oligomeric
form with an activated kinase [28, 29]. Subsequently, the
TGF-b receptor type I which alone cannot bind TGF-b is
recruited into the complex and becomes phosphorylated
by receptor II. Phosphorylation finally allows receptor
I to propagate the signal to downstream signals involv-
ing the Smad family of signal transducer proteins as well
as Smad-independent pathways [12]. These findings sug-
gest that the abundance of surface expression of TGF-b
receptor type II is the limiting factor in the initial activa-
tion of the signal transduction pathway because the type
I receptor alone cannot bind TGF-b . In agreement with
our findings, several cytokines and factors such as Ang
II, previously found to induce TGF-b receptor expres-
sion on various cells, principally up-regulate the type II
receptor [25].
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Fig. 10. Northern blot for a1(IV) collagen mRNA expression. MCT
cells were either directly stimulated with 0.5 or 2 ng/mL recombinant
transforming growth factor-b (TGF-b1) for 12 hours or were prein-
cubated for 24 hours in 1 mg/mL albumin with subsequent TGF-b1
challenge. Cells pretreated with albumin showed a stronger increase in
a1(IV) collagen mRNA induced by exogenous TGF-b1 compared with
cells grown in serum-free medium without albumin. This blot is repre-
sentative of three independent experiments with qualitatively similar
changes.
Proteinuria is associated with stimulated tubular TGF-
b synthesis [10, 30–32]. This effect may be partly mediated
by Ang II [31]. It has been previously described that ex-
posing cultured proximal tubular cells to 0.1 to 10 mg/dL
albumin leads to an increased tubular production of TGF-
b in a culture system using human proximal tubular cells
[9]. In the remnant kidney model, Abbate et al [10] ob-
served that ultrafiltered proteins are taken up by proximal
tubules. Tubular TGF-b1 mRNA expression, as detected
by in situ hybridization, was stimulated concomitantly
with protein overreabsorption. Later, peritubular accu-
mulation of a-smooth muscle actin–expressing myofi-
broblasts was found in this area [10]. It is obvious that
a parallel increase in TGF-b receptors would further am-
plify autocrine TGF-b effect after induction of this fibro-
genic cytokine in tubular cells by albuminuria.
Proximal tubular cells have a local renin-angiotensin
system that operates independently from its systemic
counterpart [33]. More than a decade ago, we have
demonstrated that MCT cells posses all components of
a functioning renin-angiotensin system [34]. In vitro and
in vivo investigations have demonstrated that tubular
cells exposed to protein revealed an increased transcrip-
tion of angiotensinogen and up-regulation of angiotensin-
converting enzyme (ACE) [26, 35]. This results in a local
increase in Ang II. Proximal tubular cells produce Ang
II in the nanomolar range and secrete it into the urine as
well as into the interstitial space [36, 37]. Renal tubuloint-
erstitial damage by persistent proteinuria is attenuated in
AT1-receptor–deficient mice suggesting a direct effect of
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Ang II in this process [39]. We and others have previously
shown that Ang II up-regulates TGF-b receptor expres-
sion [19, 25]. We found in the present study that albumin
treatment of cultured MCT cells induced an increase in
angiotensinogen and renin transcription that resulted in
a significantly enhanced production of Ang II. Thus, our
observation that losartan almost completely attenuated
the albumin-mediated increase in TGF-b type II recep-
tor expression in MCT cells together with the stimulated
Ang II formation strongly suggests that albumin leads to
tubular synthesis of Ang II which, in turn, stimulates tran-
scription of TGF-b type II receptors. The reporter gene
experiments also suggest a pivotal role for Ang II in me-
diating albumin-induced transcription of the TGF-b type
II receptor. The promoter region for this TGF-b recep-
tor contains multiple components, including two positive
regulatory elements and two negative regulatory sites in
addition to the core promoter [24]. The core promoter,
which is the 47 fragment, as well as the 504 construct that
contains an AP-1 site at −195 bp showed in our study no
significant increase in transcriptional activity after stimu-
lation with albumin. In contrast, a strong transcriptional
activity was induced by various concentrations of albumin
with the long 1240 construct that contains a second AP-1
site at −1213 bp. The protein products of c-fos and c-jun
form a heterodimer that binds to AP-1 sites. Since we
have previously demonstrated that Ang II stimulates ex-
pression of c-fos in MCT cells [16], it is intriguing to spec-
ulate that albumin induces angiotensin II that, in turn,
activates c-fos and c-jun expression in MCT cells. Ulti-
mately, this complex may bind to AP-1 sites and stimulate
the transcription of the TGF-b receptor type II.
How albumin may activate the tubular renin-
angiotensin system is currently unclear. Albumin is taken
up into proximal tubular cells through specific transport
processes [39]. Megalin and cubulin are two receptors
likely involved in this specific tubular uptake of albumin
[40, 41]. Recent studies demonstrate that albumin uptake
in proximal tubular cells induces the formation of reac-
tive oxygen species (ROS) and also activates certain sig-
nal transduction pathways such as the STAT/Jak 2 system
[42, 43]. Since ROS could up-regulate angiotensinogen
expression [44], ROS may be an important intermediate
in albumin-induced renin-angiotensin system activation.
On the other hand, Ang II stimulates the formation
of ROS through the membrane-bound NAD(P)H oxi-
dase suggesting a possibility for a positive feedback loop
[45]. Further studies beyond the scope of the present
manuscript are necessary to investigate how such a tubu-
lar uptake of albumin could then activate local renin-
angiotensin system components.
However, our study has some limitations. We used hu-
man TGF-b receptor type II promoter constructs in a
heterologous system in mice that may pose a limitation
to some of our findings. In addition, all our data were
obtained from cell culture studies. Although these MCT
cells express many properties of proximal tubular cells
in vivo [13–16], and we were able to demonstrate that
several effects discovered in these cells such as the Ang
II–induced induction of the cell cycle regulator p27Kip1
are also operative in vivo [46, 47], further in vivo stud-
ies are certainly necessary to corroborate our cell culture
findings. We are currently studying whether TGF-b re-
ceptor type II is up-regulated on tubules in puromycin
nephrosis to further test our present findings in vivo. Fi-
nally, the role of albumin as the main noxious agent in
proteinuria has been questioned [48], and other proteins
such as complement may be more important in mediat-
ing the pathomorphologic changes in tubulointerstitial
architecture associated with proteinuria.
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